Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program.
In the company’s own words · 10-K filed Feb 5, 2026 · SEC EDGAR
Business segments
Q3 2024 · $156.0KThe company’s own SEC segment disclosure.
- Collaboration$78.0K50%
- Otx Tic Product$78.0K50%
Ocular Therapeutix, Inc. (OCUL) reported revenue of $11M in Q1 2026 (quarter ended March 31, 2026), up 0.8% from the same quarter a year earlier. That came with a gross margin of 88% and net loss of $89M. For the full year FY2025, revenue was $52M (−18% year on year) and net income −$266M. Its largest product in 2024-Q3 was Collaboration at $78K, 50.0% of the disclosed total, just ahead of Otx Tic Product at 50.0%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.